Stock 3SBIO INC. (ADR)
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

3SBio Inc. (ADR) Share Price Nasdaq

Equities

US88575Y1055

Pharmaceuticals

End-of-day quote Nasdaq
Other stock markets
- USD - Intraday chart for 3SBio Inc. (ADR)
04-22 3Sbio Inc. Announces Management Changes CI
04-15 3SBIO Gets China Nod for Use of Cancer Injection in Children with Thrombocytopenia MT

Financials

Sales 2023 7.82B 1.08B 86.35B Sales 2024 * 8.65B 1.19B 95.55B Capitalization 13.41B 1.85B 148B
Net income 2023 1.55B 214M 17.11B Net income 2024 * 1.93B 267M 21.37B EV / Sales 2023 2.37 x
Net Debt 2023 2.15B 296M 23.73B Net Debt 2024 * 866M 119M 9.56B EV / Sales 2024 * 1.65 x
P/E ratio 2023
11 x
P/E ratio 2024 *
7.4 x
Employees -
Yield 2023 *
2.86%
Yield 2024 *
3.87%
Free-Float 73.92%
More Fundamentals * Assessed data

Latest news about 3SBio Inc. (ADR)

3Sbio Inc. Announces Management Changes CI
3SBIO Gets China Nod for Use of Cancer Injection in Children with Thrombocytopenia MT
3SBio Inc. Approves Recombinant Human Thrombopoietin Injection for Pediatric ITP Indication CI
3SBio Inc. commences an Equity Buyback for 243,892,041 shares, representing 10% of its issued share capital, under the authorization approved on June 20, 2023. CI
3SBio's 2023 Profit Falls 19%, EPS Misses Estimates MT
3SBio Inc. Proposes Final Dividend for the Year Ended 31 December 2023, Payable on August 05, 2024 CI
3SBio Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
China's NMPA Gives 3SBio Permission to Sell Anti-Dandruff Product MT
Mandi Foam of 3SBio Inc. Approves for Market Launch CI
Venus Medtech Names Former 3SBio Finance Chief as CFO MT
3SBio Secures Exclusive License to CStone's Anti-Tumor Drug in China MT
3SBio's H1 Attributable Profit Rises, Beats EPS Estimates MT
3SBio Inc. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
3SBio Hires Former JPMorgan Exec as CFO MT
3Sbio Inc. Announces Appointment of He Xiang as Chief Financial Officer CI
More news

Analyst Recommendations on 3SBio Inc. (ADR)

3SBio : MSCI ESG Rating Upgraded to A, Ranking at the Forefront of the Global Biotechnology Industry PU
More recommendations

Press releases 3SBio Inc. (ADR)

3SBio announces 2023 interim results, with revenue growing over 20% year on year and pipeline value constantly enhanced PR
3SBio : 2023 Interim Results Presentation PU
3SBio : 2022 ESG Report PU
3SBio announces 2022 annual results, with revenue rising 7.5% year on year and normalized net profit attributable to parents jumping 25.2% PR
3SBio : 2022 Interim Results Presentation PU
More press releases

News in other languages on 3SBio Inc. (ADR)

Cosmo renoue avec les chiffres noirs sur les six premiers mois
Morning Briefing - Markt Schweiz
Principales informations avant-Bourse
Cosmo wieder mit Gewinn im ersten Halbjahr
3SBio : La biotech chinoise 3SBio achète une filiale du canadien Therapure
More news

Managers and Directors - 3SBio Inc. (ADR)

Managers TitleAgeSince
Jing Lou CEO
 Chief Executive Officer 61 31/12/92
Xiang He DFI
 Director of Finance/CFO - 02/07/23
Dong Mei Su BRD
 Director/Board Member 54 10/06/12
Members of the board TitleAgeSince
Bin Huang BRD
 Director/Board Member 63 31/12/92
Jing Lou CEO
 Chief Executive Officer 61 31/12/92
Dong Mei Su BRD
 Director/Board Member 54 10/06/12
More insiders

Company Profile

3SBio Inc. is an investment holding company mainly engaged in the the development, production, marketing and sale of pharmaceutical products. The Company’s main products include recombinant human thrombopoietin (rhTPO) products, tumor necrosis factor (TNF)αinhibitor products and recombinant human erythropoietin (rhEPO) products. The products are sold under the name of TPIAO, Yisaipu, EPIAO and SEPO. The Company distributes its products within the domestic market and to overseas markets, including Sri Lanka, Dominican Republic and Thailand. The Company’s subsidiaries include Collected Mind Limited, Hongkong Sansheng Medical Limited and Shenyang Sunshine Pharmaceutical Co., Ltd.. Through its subsidiaries, the Company is engaged in project management and consultation.
Sector
Pharmaceuticals
Calendar
20/08/2024 - Q2 2024 Earnings Release (Projected)
More about the company

Sector Biopharmaceuticals

1st Jan change Capi.
CSL LIMITED Stock CSL Limited
-4.14% 86.13B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+1.32% 39.82B
BIOGEN INC. Stock Biogen Inc.
-19.27% 30.42B
UCB Stock UCB
+57.86% 25.23B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-16.09% 15.36B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-9.14% 11.95B
INCYTE CORPORATION Stock Incyte Corporation
-17.69% 11.6B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-43.00% 11.51B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+5.24% 8.71B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. 1530 Stock
  4. Stock